373 related articles for article (PubMed ID: 31332886)
1. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y
Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973
[TBL] [Abstract][Full Text] [Related]
4. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
5. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF
Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362
[TBL] [Abstract][Full Text] [Related]
6. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
7. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
[TBL] [Abstract][Full Text] [Related]
8. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
9. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
11. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
12. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
15. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
[TBL] [Abstract][Full Text] [Related]
16. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
[TBL] [Abstract][Full Text] [Related]
19. Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
Maimaitiaili A; Chen H; Xie P; Liu Z; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; He J; Fan Z; Zhang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8769-8778. PubMed ID: 37129606
[TBL] [Abstract][Full Text] [Related]
20. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
